Journal of Affective Disorders
Volume 102, Issue 1 , Pages 65-72 , September 2007

Tryptophan breakdown pathway in bipolar mania

  • Aye Mu Myint

      Affiliations

    • Department of Psychiatry and Neuropsychology, University of Maastricht, The Netherlands
    • Department of Medical Biochemistry, Institute of Pharmaceutical Sciences, University of Antwerp, Belgium
    • ,
  • Yong-Ku Kim

      Affiliations

    • Department of Psychiatry, Division of Brain Korea 21 Biomedical Science, College of Medicine, Korea University, Korea
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, Korea University Mediccal Center Ansan Hospital, 425-020, Ansan, South Korea.
    • ,
  • Robert Verkerk

      Affiliations

    • Department of Medical Biochemistry, Institute of Pharmaceutical Sciences, University of Antwerp, Belgium
    • ,
  • Sun Hwa Park

      Affiliations

    • Department of Anatomy, Division of Brain Korea 21 Biomedical Science, College of Medicine, Korea University, Korea
    • ,
  • Simon Scharpé

      Affiliations

    • Department of Medical Biochemistry, Institute of Pharmaceutical Sciences, University of Antwerp, Belgium
    • ,
  • Harry W.M. Steinbusch

      Affiliations

    • Department of Psychiatry and Neuropsychology, University of Maastricht, The Netherlands
    • ,
  • Brian E. Leonard

      Affiliations

    • Department of Psychiatry and Neuropsychology, University of Maastricht, The Netherlands

Received 28 September 2006 ,Revised 6 December 2006 ,Accepted 8 December 2006.

References 

  1. Angst J. The course of affective disorders. Psychopathology. 1986;19(Suppl 2):47–52
  2. Anguelova M, Benkelfat C, Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective disorders. Mol. Psychiatry. 2003;8:574–591
  3. Anguelova M, Benkelfat C, Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. Mol. Psychiatry. 2003;8:646–653
  4. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994;
  5. Askland K, Parsons M. Toward a biaxial model of “bipolar” affective disorders: Spectrum phenotypes as the products of neuroelectrical and neurochemical alterations. J. Affect. Disord. 2006;94:15–33
  6. Bellivier F, Henry C, Szoke A, Schurhoff F, Nosten-Bertrand M, Feingold J, et al. Serotonin transporter gene polymorphisms in patients with unipolar or bipolar depression. Neurosci. Lett. 1998;255:143–146
  7. Bender DA, McCreanor GM. Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism. Biochem. Soc. Trans. 1985;13:441–443
  8. Calabrese JR, Shelton MD, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am. J. Psychiatry. 2005;162:2152–2161
  9. Chiarugi A, Calvani M, Meli E, Traggiai E, Moroni F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J. Neuroimmunol. 2001;120:190–198
  10. Chuang DM. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann. N. Y. Acad. Sci. 2005;1053:195–204
  11. Collier DA, Arranz MJ, Sham P, Battersby S, Vallada H, Gill P, et al. The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. Neuroreport. 1996;7:1675–1679
  12. Cooper JD, Turnell DC, Green B, Verillon F. Automated sequential trace enrichment of dialysates and robotics. A technique for the preparation of biological samples prior to high-performance liquid chromatography. J. Chromatogr. 1988;456:53–69
  13. Coryell W, Keller M, Endicott J, Andreasen N, Clayton P, Hirschfeld R. Bipolar II illness: course and outcome over a five-year period. Psychol. Med. 1989;19:129–141
  14. Cusin C, Serretti A, Lattuada E, Mandelli L, Smeraldi E. Impact of clinical variables on illness time course in mood disorders. Psychiatry Res. 2000;97:217–227
  15. Cusin C, Serretti A, Lattuada E, Lilli R, Lorenzi C, Mandelli L, et al. Influence of 5-HTTLPR and TPH variants on illness time course in mood disorders. J. Psychiatr. Res. 2001;35:217–223
  16. De Luca V, Likhodi O, Van Tol HH, Kennedy JL, Wong AH. Tryptophan hydroxylase 2 gene expression and promoter polymorphisms in bipolar disorder and schizophrenia. Psychopharmacology (Berlin). 2005;183:378–382
  17. First M, Spitzer RL, Gibbon M, William JB. Structured Clinical Interview for DSM-IV Axis I Disorder—Patient Edition (SCID-I/P, version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute; 1998;
  18. Gal EM, Sherman AD. l-kynurenine: its synthesis and possible regulatory function in brain. Neurochem. Res. 1980;5:223–239
  19. Gonzalez-Pinto A, Ballesteros J, Aldama A, Perez de Heredia JL, Gutierrez M, Mosquera F, et al. Principal components of mania. J. Affect Disord. 2003;76:95–102
  20. Grant RS, Kapoor V. Murine glial cells regenerate NAD, after peroxide-induced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates. J. Neurochem. 1998;70:1759–1763
  21. Grant RS, Naif H, Espinosa M, Kapoor V. IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress. Redox Rep. 2000;5:101–104
  22. Herve C, Beyne P, Jamault H, Delacoux E. Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J. Chromatogr. B., Biomed. Sci. Appl. 1996;675:157–161
  23. Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 1996;320(Pt 2):595–597
  24. Hoekstra R, Fekkes D, Loonen AJ, Pepplinkhuizen L, Tuinier S, Verhoeven WM. Bipolar mania and plasma amino acids: increased levels of glycine. Eur. Neuropsychopharmacol. 2006;16:71–77
  25. Kessing LV. Recurrence in affective disorder. II. Effect of age and gender. Br. J. Psychiatry. 1998;172:29–34
  26. Kessing LV, Andersen PK, Mortensen PB, Bolwig TG. Recurrence in affective disorder. I. Case register study. Br. J. Psychiatry. 1998;172:23–28
  27. Kim JP, Choi DW. Quinolinate neurotoxicity in cortical cell culture. Neuroscience. 1987;23:423–432
  28. Mahmood T, Silverstone T. Serotonin and bipolar disorder. J. Affect Disord. 2001;66:1–11
  29. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006;1073–1074:25–37
  30. Murray CJ, Lopez AD. Evidence-based health policy—lessons from the Global Burden of Disease Study. Science. 1996;274:740–743
  31. Myint AM, Kim YK. Cytokine–serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypotheses. 2003;61:519–525
  32. Myint A, Kim YK, Verkerk R, Scharpe S, Steinbusch HWM, Leonard BE. Kynurenine pathway in major depression: Evidence of impaired neuroprotection. J Affect Disord. 2007;98:143–151
  33. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol. Rep. 1962;10:799–812
  34. Perkins MN, Stone TW. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 1982;247:184–187
  35. Sanacora G, Rothman DL, Mason G, Krystal JH. Clinical studies implementing glutamate neurotransmission in mood disorders. Ann. N. Y. Acad. Sci. 2003;1003:292–308
  36. Schwarcz R, Whetsell WO, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 1983;219:316–318
  37. Serretti A, Lilli R, Lorenzi C, Lattuada E, Cusin C, Smeraldi E. Serotonin transporter gene (5-HTTLPR) and major psychoses. Mol. Psychiatry. 2002;7:95–99
  38. Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 2002;1:609–620
  39. Vriend JP, Alexiuk NA. Effects of valproate on amino acid and monoamine concentrations in striatum of audiogenic seizure-prone Balb/c mice. Mol. Chem. Neuropathol. 1996;27:307–324
  40. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology. 1998;38:119–130
  41. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry. 1978;133:429–435

PII: S0165-0327(06)00540-4

doi: 10.1016/j.jad.2006.12.008

Journal of Affective Disorders
Volume 102, Issue 1 , Pages 65-72 , September 2007

Article Tools

* Image Usage & Resolution